论文部分内容阅读
目的探讨肝细胞生长因子(HGF)在上皮性卵巢癌血清中含量及其与卵巢癌早期诊断的关系。方法血清HGF测定采用固相酶联免疫吸附试实验(ELISA)双抗体夹心法检测。结果①上皮性卵巢癌血清HGF各临床分期之间分别比较,P<0.05,差异有显著性;②上皮性卵巢癌血清HGF各病理分级之间分别比较,P<0.05,差异有显著性;③HGF和CA125对卵巢癌诊断敏感率分别为91.3%和38%,与二者联合检测相比较,P<0.05,差异有显著性。结论血清HGF值与卵巢癌临床分期和病理分级均有关,通过对HGF及血清CA-125的联合检测可以对高危人群进行早期筛查,以提高卵巢癌的早期诊断率。
Objective To investigate the serum levels of hepatocyte growth factor (HGF) in epithelial ovarian cancer and its relationship with early diagnosis of ovarian cancer. Methods Serum HGF was detected by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich method. Results ① The clinical stages of HGF in epithelial ovarian cancer were respectively compared with each other, P <0.05, the difference was significant; ② The histological grade of serum HGF in epithelial ovarian cancer were respectively compared with each other, P <0.05, the difference was significant; ③HGF And CA125 for ovarian cancer were 91.3% and 38%, respectively, which were significantly different from the combined detection of both (P <0.05). Conclusions The serum HGF level is related to the clinical stage and pathological grade of ovarian cancer. By combining the detection of HGF and serum CA-125, early screening of high-risk population can be conducted to improve the early diagnosis rate of ovarian cancer.